Innovative Platform Yurogen Biosystems specializes in developing high-affinity monoclonal antibodies using an advanced screening platform, offering clients faster and more reliable antibody development, which could attract pharmaceutical and diagnostic companies seeking efficient antibody solutions.

Strategic Acquisition As a subsidiary of ABclonal Science, Yurogen benefits from integrated resources and expanded market reach, providing potential cross-selling opportunities to clients already engaged with ABclonal’s broader biotech portfolio.

Biotech Hub Location Based in the Greater Boston area, a global biotech epicenter, Yurogen has access to a vibrant network of research institutions and biotech firms, opening doors for collaborative projects and targeted outreach in one of the most active biotech markets.

Customized Solutions Offering tailored antibody services to meet specific client needs presents a sales opportunity to biotech, academic, and diagnostic clients seeking specialized antibodies for research and in vitro diagnostics applications.

Growing Market Segment With revenue estimates of up to 25 million dollars and a focus on antibody-based products, Yurogen’s positioning in the antibody and diagnostic market makes it a compelling partner for organizations developing novel diagnostics or therapeutic research tools.